Metabolism, Diabetes, and Cancer

Study links GLP-1 drugs with lower dementia risk than long-acting insulin

In a large study of adults over 50 with type 2 diabetes in Taiwan, new dementia diagnoses were less frequent among people who started a GLP-1 receptor agonist than among matched people who started long-acting insulin. The study was observational, so it cannot determine whether the medicines caused the difference.